ClinicalTrials.gg
Status unknownNCT03057574GIVFUpdated Aug 30, 2017

Gonapure® in Multifollicular Stimulation in Egyptian Women Undergoing IVF/ICSI

A Phase 4 interventional study of Follitropin Alfa in Female Infertility, sponsored by MinaPharm Pharmaceuticals. Status unknown at 2 sites in Egypt. Open to female participants aged 18 Years to 38 Years. Per ClinicalTrials.gov, last updated 2017-08-30.

Sponsored by MinaPharm Pharmaceuticals · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2017), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years to 38 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies in Infertility, Female with a site in Egypt — 6 open to participants now, 6 under way, none of them phase 3. Infertility, Female · Egypt.

Planned enrollment
7th of 46
200 · median 141
Started
2017
with 8 others
Phase 4
15 of 60
1 open now
Registered
6th of 60
by date

Among the 60 studies in Infertility, Female with a site in Egypt, this one is the 7th largest by planned enrollment of the 46 interventional ones that give a count, is one of 9 that started in 2017, is one of 15 in phase 4, and was the 6th registered.

Infertility, Female

552 studies on the registry are indexed under Infertility, Female; 135 are open to participants now.

Browse Infertility, Female studies →

Open to participants now

6 of the 60 studies in Infertility, Female with a site in Egypt are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 90 Infertility, Female studies recruiting now, 11 (12%) set no upper age limit and 79 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 38 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Infertility, Female with a site in Egypt, or all of them as a file.
02

Study summary

This study aims to record Efficacy, Safety and tolerability of Gonapure® prescribed for female subjects with infertility Undergoing IVF/ICSI

Read the detailed description

Gonapure® is a human follicle stimulating hormone (FSH) preparation of recombinant DNA origin and contains no luteinizing hormone (LH) activity.

FSH stimulates ovarian follicular growth in women who do not have primary ovarian failure. FSH, the active component of Gonapure® is the primary hormone responsible for follicular recruitment and development. In order to affect final maturation of the follicle and ovulation in the absence of an endogenous LH surge, human chorionic gonadotropin (hCG) must be given following the administration of FSH, when monitoring of the patient indicates that sufficient follicular development has occurred. There is inter-patient variability in response to FSH administration.

The dosage and schedule of treatment for female infertility must be determined according to the needs of each patient; it is usual to monitor response by studying the patient's serum oestrogen level and/or by ultrasonic visualization of follicles.

Treatment should be started within the first 7 days of the menstrual cycle. Treatment is usually begun with 75 to 450 International units daily by intramuscular injection for 7 to 10 days; followed by individual adjustments according to the patient's follicular response i.e. until an adequate, but not excessive, response is achieved.

The investigator will decide the starting dose according to the standard clinical practice (and within the approved label).

Treatment is then stopped and followed after 1 or 2 days by a single dose of human chorionic Gonadotropin 10000 International units to induce oocyte maturation.

03

Conditions studied

  • Female Infertility

Browse trials for

04

Who can participate

Ages eligible
18 Years to 38 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female subjects aged between 18 and 38 years.
  2. Female subjects with (BMI) ≥ 18 and ≤ 40 kilogram per square meter (kg/m\^2)
  3. Female subjects with basal FSH less than 10 IU/L and PRL serum values within the normal range in the early follicular phase.
  4. Female subjects having both ovaries.
  5. Female subjects with normal uterine cavity, which in the investigator's opinion is compatible with pregnancy.
  6. Female subjects who have at least 1 wash-out cycle (defined as greater than or equal to 30 days since the last dose of clomiphene citrate or gonadotrophin treatment) since the last ART cycle and/or clomiphene citrate or gonadotrophin treatment prior to starting gonadotropin releasing hormone (GnRH) agonist therapy.
  7. Female subjects who are willing and able to comply with the protocol for the duration of the trial
  8. Female subjects who have given written , prior to any trial-related procedure, with the understanding that consent may be withdrawn by the subject at any time without prejudice to her future medical care.

Exclusion criteria

Exclusion Criteria:

  1. Female subjects with any medical condition, which in the judgment of the investigator may interfere with the absorption, distribution, metabolism or excretion of the drug.
  2. Female subjects with uterine myoma requiring treatment.
  3. Female subjects with any of being pregnant and/or carrying a pregnancy to term.
  4. Female subjects with history of tumors of the hypothalamus and pituitary gland.
  5. Female subjects with history of ovarian, uterine or mammary cancer.
  6. Female subjects with history of to the active substance follitropin alpha, FSH, or to any of the of Gonapure ®.
  7. Female subjects with untreated hydrosalpinx diagnosed by U/S.
  8. Female subjects with abnormal gynecological bleeding of unknown etiology.
  9. Female subjects with any medical condition which, in the opinion of the investigator, would prevent an effective response, such as primary ovarian failure, or malformations of the reproductive organs incompatible with pregnancy.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Treatment

    Follitropin Alfa (Gonapure)

    Drug: Follitropin Alfa

Interventions

  • Patients must be prescribed Follitropin Alfa (Gonapure®)

    Also known as: Gonapure ®

06

What researchers measure

Primary outcomes

  1. Number of oocytes retrieved on the day of Ovum Pick-Up

    Time frame: 50 days after baseline visit (EOS)

  2. Number of Mature Oocytes (MII) Retrieved Per Participant

    Metaphase II (MII): The oocyte is in the second phase of meiosis and is mature. Oocytes at this stage of maturity are ready for fertilization. Mean number of Mature oocytes (MII) retrieved on the day of ovum pick up (OPU) will be calculated. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.

    Time frame: 50 days after baseline visit (EOS)

  3. Quality of Oocytes Retrieved per participant

    It is graded on a good-fair-poor scale: * Good * Clear cytoplasm/normal shape * Single distinct polar body * Clear/thin zona pellucida * Fair * Slightly grainy cytoplasm/misshapen * Fragmented/abnormal polar body * Slightly pigmented/amorphous zona * Cytoplasmic bodies * PV (vitelline platelets) debris * Poor * Dark/grainy cytoplasm/misshapen * \>1 polar body structure * Pigmented/thickened zona * Vacuoles * PV (vitelline platelets) debris * Good Quality embryos per participant. Those embryos that have reached the most advanced developmental stage and have the least cellular fragmentation (Grades "A" and/or "B") will be considered Good Quality embryos and will be selected for transfer. * Number of transferred embryos per participant. * Percentage of Participants with Clinical Pregnancy. Clinical pregnancy is defined by the number of sacs and hearts with activity per ultrasound scan.

    Time frame: 50 days after baseline visit (EOS)

Secondary outcomes

  1. Eventual AE/SAEs related to the administration of Gonapure®

    Time frame: 50 days after baseline visit (EOS)

  2. Total & Mean Gonapure ® Daily Dose

    Time Frame: Start of treatment until end of stimulation cycle

    Time frame: 14 days

  3. Number of follicles ≥ 18 mm on day of administration of hCG

    Time frame: 50 days after baseline visit (EOS)

  4. Number of Participants with Multiple Pregnancies

    Multiple pregnancies were defined as 2 or more fetal hearts with activity.

    Time frame: 50 days after baseline visit (EOS)

  5. Number of Participants with Ovarian Hyperstimulation Syndrome

    OHSS is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid Accumulation, hemoconcentration, and increased blood clotting.

    Time frame: 50 days after baseline visit (EOS)

07

Study locations

1 of 2 sites recruiting
  • Alexandria University
    Alexandria, Egypt
    Recruiting
    • Emad Khalefa, PhD · Contact
  • Ain Shams University
    Cairo, Egypt
    Completed
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2017 (actual). Primary completion is estimated for Dec 2017, 10 months after the start.

Of 37 phase 4 interventional studies under Infertility, Female, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2016
First posted
Feb 20, 2017
StartActual
Feb 9, 2017
Primary completionEst.
Dec 2017
CompletionEst.
Jan 2018
Last update
Aug 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03057574
Lead sponsor
MinaPharm Pharmaceuticals
Responsible party
Sponsor
First posted
Feb 20, 2017
Start date
Feb 9, 2017
Primary completion
Dec 2017 (estimated)
Completion
Jan 2018 (estimated)
Last update
Aug 30, 2017

Study contacts

Ashraf Kortam, PhD
Contact
oeissa@minapharm.com
+201001433714
Emad Khalefa, PhD
Contact
oeissa@minapharm.com
Ashraf Kortam, PhD
principal investigator · Ain Shams University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin alfa

Start the discussion